Evidence map›Paper›PMID 38139773›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Nanostructured Lipid Carriers as Robust Systems for Lupeol Delivery in the Treatment of Experimental Visceral Leishmaniasis.

Jéssica Adriana Jesus, Thays Nicolli Fragoso da Silva, Ilza Maria Oliveira Sousa, Aurea Favero Ferreira, Márcia Dalastra Laurenti, Paulo Cardoso da Costa, Domingos de Carvalho Ferreira, Luiz Felipe Domingues Passero

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Jéssica Adriana JesusInstitute of Biosciences, São Paulo State University (UNESP), Praça Infante Dom Henrique, s/n, São Vicente 11330-900, SP, Brazil.ORCID 0000-0002-7212-5094
Thays Nicolli Fragoso da SilvaLaboratório de Patologia Clínica, Departamento de Patologia, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Av. Dr. Arnaldo, 455, Cerqueira César, São Paulo 05403-000, SP, Brazil.
Ilza Maria Oliveira SousaFaculty of Medical Sciences, University of Campinas-UNICAMP, Rua Tessália Vieira de Camargo, 126, Campinas 13083-871, SP, Brazil.
Aurea Favero FerreiraLaboratório de Patologia Clínica, Departamento de Patologia, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Av. Dr. Arnaldo, 455, Cerqueira César, São Paulo 05403-000, SP, Brazil.
Márcia Dalastra LaurentiLaboratório de Patologia Clínica, Departamento de Patologia, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Av. Dr. Arnaldo, 455, Cerqueira César, São Paulo 05403-000, SP, Brazil.ORCID 0000-0002-1080-2440
Paulo Cardoso da CostaUCIBIO, REQUIMTE, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge de Viterbo Ferreira, 228, 4050-313 Porto, Portugal.ORCID 0000-0002-1152-3398
Domingos de Carvalho FerreiraUCIBIO, REQUIMTE, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge de Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
Luiz Felipe Domingues PasseroInstitute of Biosciences, São Paulo State University (UNESP), Praça Infante Dom Henrique, s/n, São Vicente 11330-900, SP, Brazil.ORCID 0000-0002-5986-6381
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRUniversidade do Porto · PTUniversidade Estadual Paulista (Unesp) · BRUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

Applied Molecular Biosciences LA/P/0140/2020Fundação para a Ciência e Tecnologia UIDP/04378/2020; UIDB/04378/2020HCFMUSP-LIM50 LIM50National Council for Scientific and Technological Development LFDP; MDLPROPe-UNESP 05/2023/PROPeSão Paulo Research Foundation 2016/10324-6; 2018/07885-1; 2018/24077-6; 2023/01641-1
6 · The paper itself

Abstract

Leishmaniasis is a neglected tropical disease that affects millions of people around the world. Available therapy causes severe side effects, has unacceptable prices for some specific formulations, and the existence of drug-resistant parasites limits the use of the currently available arsenal of antiparasitic drugs. Therefore, natural products serve as one of the main sources to develop new and effective alternative drugs against leishmaniasis. In this sense, the present study evaluated the potential of the triterpene Lupeol (Lu) entrapped in nanostructured lipid carriers (NLCs) for the treatment of experimental visceral leishmaniasis. The therapeutic efficacy of Lu or Lu entrapped in NLC (Lu-NLC) was investigated in golden hamsters infected with

Indexed as

drug delivery systemlipid nanocarrierslupeolnanostructured lipid carriersvisceral leishmaniasis

Identifiers

PMID38139773
PMCPMC10747346
OpenAlexW4388942586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.